Journal Club Review: Pharmacokinetic Aspects of the Two Novel Oral Drugs - Charles Ryan

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide 
Guillemette E. Benoist, Rianne J. Hendricks, Peter F. A. Mulders, Winald R. Gerritsen, Diederik M. Somford, Jack A. Schalken, Inge M. van Oort, David M. Burger, Nielka P. van Erp

In this Journal Club presentation, Dr. Charles Ryan's key points include how an understanding of the pharmacology of abiraterone and enzalutamide can guide rational therapeutic decision-making based on patient-specific characteristics.  In addition, the drug-drug interactions, bioavailability and dosage that should be recognized in order to optimize treatment in patients with mCRPC.  

Read the Abstract

Biography:

Charles J. Ryan
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe